Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

Authors: James Chih-Hsin Yang, MD, PhD, Karen L. Reckamp, MD, Young-Chul Kim, MD, PhD, Silvia Novello, MD, PhD, Egbert F. Smit, MD, PhD, Jong-Seok Lee, MD, PhD, Wu-Chou Su, MD, Wallace L. Akerley, MD, Collin M. Blakely, MD, PhD, Harry J.M. Groen, MD, PhD, Lyudmila Bazhenova, MD, Enric Carcereny Costa, MD, Rita Chiari, MD, PhD, Te-Chun Hsia, MD, PhD, Tony Golsorkhi, MD, Darrin Despain, MStat, Danny Shih, BA, Sanjay Popat, BSc, MBBS, FRCP, PhD, Heather Wakelee, MD

Source: JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100114- (2021)

Subject Terms: EGFR tyrosine kinase inhibitor, Epidermal growth factor receptor mutations, Non–small cell lung cancer, Phase III randomized clinical trial, Rociletinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364320301600; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/3960fcdf0ad54bcf8d21572f501bc5e5

This result is not displayed to guests.
Login for full access.